Source: Eur Respir J 2016; 47:1591-1592



Rating:

Share or cite this content

Citations should be made in the following way:
Berry Catherine, Yates Tom A., Seddon James A., Phillips Patrick P. J., du Cros Philipp. Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China. Eur Respir J 2016; 47:1591-1592

Member's Comments

No comment yet.

Related content which might interest you: Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis Source: Eur Respir J 2012; 40: 1430-1442 Year: 2012 Efficacy and tolerability of linezolid in the treatment of MDR-TB cases: a TBNET study in Germany and Italy Source: Annual Congress 2008 - Multidrug-resistant and the emerging threat of extensively drug-resistant tuberculosis Year: 2008 A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis Source: Eur Respir J 2009; 33: 387-393 Year: 2009 Efficacy and safety of meropenem–clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB Source: Eur Respir J 2013; 41: 1386-1392 Year: 2013 Safety, tolerability and efficacy of linezolid for the treatment of M/XDR-TB: A systematic review and meta-analysis Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011 On linezolid efficacy and tolerability Source: Eur Respir J 2012; 39: 770-772 Year: 2012 Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study Source: Eur Respir J, 49 (5) 1700387; 10.1183/13993003.00387-2017 Year: 2017 Safety and tolerability of clarithromycin in the treatment of multidrug-resistant tuberculosis Source: Eur Respir J , 49 (3) 1601612; DOI: 10.1183/13993003.01612-2016 Year: 2017 Assessment of linezolid efficacy and safety in MDR- and XDR-TB: an Indian perspective Source: Eur Respir J 2010; 35: 936-938 Year: 2010 Efficacy and tolerability of linezolid in multidrug-resistant tuberculosis (MDR/XDR-TB) Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008 Linezolid safety, tolerability and efficacy to treat multidrug- and extensively drug-resistant tuberculosis Source: Eur Respir J 2011; 38: 730-733 Year: 2011 Efficacy and safety of chemotherapy regimens containing fluoroquinolones in pediatric TB Source: Virtual Congress 2021 – Epidemiology and burden of tuberculosis and other lung diseases Year: 2021 Evaluation of the efficacy and safety of moxifloxacin in the treatment of drug-resistant pulmonary tuberculosis; a clinical trial Source: Annual Congress 2008 - Multidrug-resistant and the emerging threat of extensively drug-resistant tuberculosis Year: 2008 Evaluation of the efficacy and safety of levofloxacin in the treatment of resistant pulmonary tuberculosis; a clinical trial Source: Eur Respir J 2002; 20: Suppl. 38, 546s Year: 2002 The efficacy, safety and tolerability of the short 12-month MDR-TB regimen in Ukraine at the expense of using intravenous administration of anti-tuberculosis drugs during intensive phase Source: International Congress 2017 – Treatment of multi-drug-resistant tuberculosis (MDRTB): where are we now? Year: 2017 The efficacy, safety and tolerability of the short 12-month pre-XDR-TB regimen regimen in Ukraine at the expense of using intravenous administration of anti-tuberculosis drugs during intensive phase Source: International Congress 2017 – Paediatric TB: MDRTB (II) Year: 2017 Linezolid: safety and efficacy monitoring Source: Eur Respir J 2012; 39: 1276-1277 Year: 2012 Linezolid: safety and efficacy monitoring Source: Eur Respir J 2012; 39: 1275-1276 Year: 2012 Clinical efficacy and safety of clarithromycin in the treatment of multi-drug resistant tuberculosis Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance Year: 2009 Evaluation of efficacy and safety of linezolid for the treatment of drug-resistant tuberculosis: case series report of 12 patients Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance Year: 2009